Home › A Pediatric Endocrinologist's View Of MannKind's Afrezza
 

Keywords :   


A Pediatric Endocrinologist's View Of MannKind's Afrezza

2015-11-05 13:08:14| Biotech - Topix.net

There have been many investment analyst opinions expressed about the coming success or failure of MannKind Corporation's new inhaled insulin, Afrezza. Sanofi , MannKind's pharmaceutical marketing partner, has invested millions of dollars in up front licensing fees, milestone payments, and Afrezza related costs in marketing and promotion.

Tags: view pediatric afrezza

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
21.09Strategies to minimize fallback pigs in the nursery
21.09This Week in Agribusiness, Sept. 21, 2024
21.09This Week in Agribusiness, Sept. 21, 2024
21.09RABapp provides rapid response insight in animal health emergencies
21.09Atlantic Tropical Weather Outlook
21.09Eastern North Pacific Tropical Weather Outlook
21.09Weekly Recap: PPG, Axalta, AkzoNobel Top This Weeks Stories
21.09Atlantic Tropical Weather Outlook
More »